Thus, we investigated the potential influence of NTF3 expression on cancer immunotherapy and found a positive correlation between NTF3 expression and immune checkpoints, including PD-L1, TIGIT, and TIM-3, but not CTLA4 (Figure 8B). Here, HAVCR2 is linked to cancer.